Table 2. Immunohistochemistry – summary of clinical and histopathological data.
| Total (n=78) |
HIWI staininga
|
Patients at follow-up
|
||||
|---|---|---|---|---|---|---|
| CP (n=10) | CP/nucleus (n=11) | No staining (n=57) | Aliveb (n=10) | Deadc (n=68) | ||
| Men/women | 47/31 | 7/3 | 6/5 | 34/23 | 5/5 | 42/26 |
| Tumour stage (%) | ||||||
| I | 6 | 1 (16.7%) | 2 (33.3%) | 3 (50.0%) | 2 (33.3%) | 4 (66.6%) |
| II | 12 | 1 (8.3%) | 0 (0%) | 11 (91.6%) | 2 (16.7%) | 10 (83.3%) |
| III | 53 | 7 (13.2%) | 7 (13.2%) | 39 (73.6%) | 6 (11.3%) | 47 (88.7%) |
| IV | 7 | 1 (14.3%) | 2 (28.6%) | 4 (57.1%) | 0 (0%) | 7 (100%) |
| Tumour resection (%) | ||||||
| Radical (R0) | 60 | 7 (11.7%) | 8 (13.3%) | 45 (75.0%) | 9 (15.0%) | 51 (85.0%) |
| Not radical (R1) | 11 | 1 (9.1%) | 2 (18.2%) | 8 (72.7%) | 1 (9.1%) | 10 (90.1%) |
| Not radical (R2) | 7 | 2 (28.6%) | 1 (14.3%) | 4 (57.1%) | 0 (0%) | 7 (100%) |
| Tumour grading (%) | ||||||
| G1 | 7 | 1 (14.3%) | 0 (0%) | 6 (85.7%) | 2 (28.6%) | 5 (71.4%) |
| G2 | 30 | 5 (16.7%) | 4 (13.3%) | 21 (70%) | 4 (13.3%) | 26 (86.7%) |
| G3 | 41 | 4 (9.7%) | 7 (17.1%) | 30 (73,2%) | 4 (9.7%) | 37 (90.3%) |
| Patients at follow-up (%) | ||||||
| Aliveb | 10 | 0 (0%) | 2 (20.0%) | 8 (80.0%) | 10 | |
| Deadc | 68 | 10 (14.7%) | 9 (13.2%) | 49 (72.1%) | 68 | |
Data are the number of patients.
a
Staining patterns: CP–isolated cytoplasmatic staining; CP/nucleus–simultaneous cytoplasmatic and nuclear staining.
b
After an average observation time of 15.99 (range 1–61) months.
c
Patients died after an average of 15.26 (range 1–49) months, four patients died from non-tumour-related causes.